Navigation Links
Annual SNM MI summit introduces the clinical trials network
Date:1/13/2009

and protocol is key to quality data generation and ultimate FDA approval of investigational therapeutics.

"It is important that interested imaging centers, drug manufacturers and other facilities get involved at this time as there are steps to be taken to ensure imaging standardization and to maintain imaging quality control across multiple sites," added Atcher. "This workshop will give members of the molecular imaging community an overview of the network and specific steps that participating imaging sites can take to ensure that they are qualified for participation in therapeutic clinical trialsand remain qualified over time. Speakers from the Food and Drug Administration, National Cancer Institute, pharmaceutical development industry and the imaging community will share their thoughts on specific needs for imaging biomarkers in drug development and the unique issues involved with incorporating imaging into multi-center clinical trials.

This comprehensive workshop will be held immediately after SNM's Mid-Winter Educational Symposium. It is slated to include presentations and discussions about: methods and short-comings of current drug development practices; the potential for imaging biomarkers in multi-center clinical trials; the role of the Clinical Trials Network in drug development; and fundamentals of participation in this network. SNM will discuss the specific goals and detailed plans of the Clinical Trials Network, including the roles and responsibilities of participation in network imaging and manufacturing registries, the phantom program and the 2009 F-18-fluorothymidine (FLT) demonstration project. Representatives from drug trial sponsors will discuss the specific needs for imaging in multi-center clinical trials.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Agito Networks Earns INTERNET TELEPHONY Magazines 11th Annual Product of the Year Award
3. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
4. WebMD to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. drugstore.com to Present at the 11th Annual ICR XChange Conference
6. Hop the Trolley for DNAs 27th Annual Conference
7. Almost Family to Present at 27th Annual J.P. Morgan Healthcare Conference
8. Society of Gynecologic Oncologists to Host 40th Annual Meeting on Womens Cancer
9. Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue
10. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
11. VNUS Medical Technologies to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14 2009 56735 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 1Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 2Tianyin Pharmaceutical Co Inc Has Four Products Included in Chinas Essential Drug List 56734 3MDS Reports Third Quarter 2009 Financial Results 56733 1MDS Reports Third Quarter 2009 Financial Results 56733 2MDS Reports Third Quarter 2009 Financial Results 56733 3MDS Reports Third Quarter 2009 Financial Results 56733 4MDS Reports Third Quarter 2009 Financial Results 56733 5MDS Reports Third Quarter 2009 Financial Results 56733 6MDS Reports Third Quarter 2009 Financial Results 56733 7MDS Reports Third Quarter 2009 Financial Results 56733 8MDS Reports Third Quarter 2009 Financial Results 56733 9MDS Reports Third Quarter 2009 Financial Results 56733 10MDS Reports Third Quarter 2009 Financial Results 56733 11MDS Reports Third Quarter 2009 Financial Results 56733 12MDS Reports Third Quarter 2009 Financial Results 56733 13MDS Reports Third Quarter 2009 Financial Results 56733 14MDS Reports Third Quarter 2009 Financial Results 56733 15MDS Reports Third Quarter 2009 Financial Results 56733 16MDS Reports Third Quarter 2009 Financial Results 56733 17MDS Reports Third Quarter 2009 Financial Results 56733 18MDS Reports Third Quarter 2009 Financial Results 56733 19MDS Reports Third Quarter 2009 Financial Results 56733 20MDS Reports Third Quarter 2009 Financial Results 56733 21MDS Reports Third Quarter 2009 Financial Results 56733 22MDS Reports Third Quarter 2009 Financial Results 56733 23
Other Medicine Technology:NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8